Fill, shell, stability, and packaging questions for supplement brands
A useful softgel manufacturing brief does more than name an ingredient and a bottle count. It connects the target dose to a workable fill system, a compatible shell, a stability plan, and packaging that protects the finished product.
Giving a manufacturer those decisions and open questions early makes feasibility review, sampling, specification development, and quoting more productive.
This guide gives supplement founders, product teams, and procurement staff a practical structure for preparing that brief.
It does not replace formulation, quality, regulatory, or stability work by qualified professionals. Product-specific requirements must be confirmed with the manufacturer and the brand’s quality and regulatory advisers.
What a Softgel Manufacturing Brief Needs to Accomplish
The brief should define the intended finished product clearly enough for a manufacturer to identify feasibility gaps before pricing it. That means separating facts, preferences, and unresolved technical questions.
A target such as “one softgel per serving” is a preference until the dose, concentration, fill volume, and available tooling show that it is practical.
Start by stating whether the project uses a stock formula, adapts an existing formula, transfers a product from another manufacturer, or begins with a new concept. CPack’s stock softgel catalog and custom softgel manufacturing service represent different development paths, so the brief should identify which route the brand expects to explore.
Define the Fill Before Choosing the Shell
The fill drives softgel feasibility. List every active and inactive ingredient, the source or grade when known, the amount per serving, the desired serving size, and whether the ingredient will be dissolved or suspended. Include target claims only as review inputs, not as proof that the formula or label is acceptable.
Fill behavior matters because a softgel is a coupled fill-and-shell system. A peer-reviewed review of softgel shell formulation and characterization explains that fill-shell interactions, temperature, humidity, and ingredient migration can change shell performance over time.
Another review on soft gelatin capsule dissolution development identifies particle size, temperature, viscosity, and compatibility as important fill considerations.
Ask the manufacturer what data it needs to evaluate solubility, suspension behavior, oxidation risk, viscosity, fill-weight range, and ingredient compatibility.
If the formula already exists, provide its current specification and test methods under an appropriate confidentiality agreement instead of translating it into marketing language.
Choose Shell and Dosage Form Together
Shell material is a technical and commercial decision, not a cosmetic option added at the end. State any dietary, allergen, certification, market, color, opacity, printing, shape, and swallowing requirements. Then ask which available shell systems are compatible with the fill and target shelf life.
Do not assume that “vegetarian,” “gelatin,” or “enteric” describes a universally interchangeable shell. Available materials, tooling, minimum run sizes, validation work, and claim support can differ by manufacturer and product. The brief should rank requirements as mandatory, preferred, or open to recommendation so the technical team can explain tradeoffs instead of guessing priorities.
This section should also define the target count per serving and any size limits. A dose that cannot fit into the preferred unit may require a larger softgel, more units per serving, a more concentrated fill, or a different dosage form. For broader format and scheduling context, review CPack’s supplement manufacturing lead-time guide while treating all timing as project-specific until confirmed.
Build Stability Questions Into the Brief
A shelf-life target is not a stability plan. The brief should identify ingredients sensitive to oxygen, moisture, heat, or light; the intended shelf life; expected storage statements; launch markets; and any known degradation pathways.
Ask who designs the protocol, which attributes are tested, what packaging configuration is studied, and how changes will be assessed.
The applicable specifications must be defined before release decisions can be meaningful. Under 21 CFR 111.70, dietary supplement manufacturers must establish component, in-process, finished-product, packaging, and labeling specifications where required to ensure quality.
The rule does not provide one universal softgel test panel, so the brand and manufacturer must define a product-specific scope with qualified quality and regulatory input.
Document what happens if a result, sample, or packaging component changes. CPack’s article on changing supplement packaging without automatic reformulation or retesting is useful background, but the decision still depends on the product, data, and proposed change.
Specify Packaging and Distribution Conditions
Packaging belongs in the development brief because it becomes part of the product’s protection system. List the preferred container, count, closure, induction seal, desiccant or oxygen-control preference, label format, secondary packaging, case pack, and distribution environment. Mark unconfirmed items clearly.
Ask which package options should be evaluated against moisture, oxygen, light, leakage, sticking, brittleness, and temperature exposure for the specific fill and shell. Section 111.70 requires contact packaging to be safe and suitable and not reactive, absorptive, or otherwise harmful to product quality. It also requires finished packaging and labeling specifications.
Distribution details matter too. Include likely warehouse conditions, parcel or freight shipping, seasonal temperature exposure, and any export markets. A package that performs in controlled storage may face different risks in a hot vehicle, humid warehouse, or long distribution lane.
Softgel Manufacturing Brief Checklist
Use the checklist to expose missing decisions, not to pretend every field is already final. A manufacturer can respond more precisely when each item is labeled confirmed, preferred, or open.
What to Send for a Useful Quote
A quote is only comparable when its assumptions are visible. Send the latest formula or concept, formula status, target dose and count, shell requirements, packaging configuration, estimated quantity or forecast range, required tests and documents, destination markets, and target timing.
Ask the manufacturer to list exclusions, client-supplied items, third-party work, decision deadlines, and change triggers.
MOQ should be expressed in the unit that matters to the buyer, such as softgels, bottles, or batch size. CPack’s supplement manufacturing MOQ guide explains why those quantities are not interchangeable.
Quality expectations should also be explicit; the GMP certification guide for supplement brands provides useful background, while project-specific documentation still needs direct confirmation.
For a project review, submit these inputs through CPack’s supplement manufacturing quote request. Do not treat an initial response as approval of feasibility, claims, specifications, stability, price, MOQ, or completion date until those points are documented for the actual project.
Frequently Asked Questions
At minimum, provide the product concept, formula status, target dose, serving count, shell preferences, packaging format, quantity range, markets, and timing. Flag missing data so the manufacturer can tell you what is required for feasibility review.
Usually, the fill and shell should be evaluated together. Dietary and market requirements may narrow shell options, but compatibility, moisture exchange, migration, and stability can make a preferred shell unsuitable for a specific fill.
Ask what protocol, test attributes, packaging configuration, storage conditions, pull points, acceptance criteria, and responsibilities apply. The answer should be tied to the actual ingredients, shell, claims, shelf-life target, and markets.
Not always, but the likely packaging system should enter the discussion early. Container protection, closure, count, headspace, light exposure, shipping conditions, and line compatibility may affect development and stability decisions.
Detailed enough to identify the intended specifications, test methods, records, release roles, deviations, and change controls. The written master manufacturing record must be unique to the formulation and batch size under 21 CFR 111.205, and 21 CFR 111.210 lists required content, including components, packaging, labels, instructions, sampling, and corrective actions.
